SIRT5 and Sepsis: Nonetheless, putting together the data from the present study together with the fact that single deficiencies in SIRT3 and SIRT5 had no impact in a large panel of experimental sepsis (37–40), one may foresee that therapies directed against mitochondrial sirtuins or concomitant targeting of SIRT3 and SIRT5 activity should have no deep impact on antibacterial host defenses.